We are supporting a range of international opportunities for researchers looking to validate and progress targets for neurodegenerative diseases.

Alzheimer’s Research UK is committed to creating a supportive environment that encourages and helps the translation of the most promising discoveries towards new treatments for people with dementia.

To date, we have invested more than £66m into the Drug Discovery Alliance, with a further £45m for 2026-2031, subject to annual reviews. 

Collaborate with us

From target validation to in vivo proof of concept, we have a range of opportunities to help develop your most promising ideas into treatments for people affected by dementia.

We encourage dialogue about potential collaborations at any stage. Contact us at research@alzheimersresearchuk.org

Scientists in the lab

Drug Discovery Alliance

An ambitious £91m initiative focusing on early drug target identification and validation for neurodegeneration.

scientist using microscope

Dementia Discovery Fund

A close collaboration between charity, industry and the government, to provide investment to nurture projects through the pre-clinical phase.

Not sure which option is suitable for you?

Described above are a number of vehicles for funding and executing specific translational projects that Alzheimer’s Research UK has developed. Each has unique advantages that may be beneficial depending upon the status of your project or the type of enterprise you are seeking to form.

Oftentimes, university technology transfer offices will have valuable experience to help you consider which of these represents the best approach for your project’s progression.

You can consider the grants and initiatives below as well:

Specific Alzheimer’s Research UK grants and initiatives

Among the various Alzheimer’s Research UK grant schemes, some are designed to fund critical experiments to enable a successful application to other translational vehicles:

For further information and advice, please contact research@alzheimersresearchuk.org